Clopidogrel for atrial fibrillation to limit the risk of cardiovascular events can be appropriate in cases where patients cannot tolerate vitamin K antagonists like warfarin. This medication is not considered as effective as warfarin, but offers more protection than some other therapies, and can be a suitable alternative for patients. Before a doctor recommends a therapy for a patient with atrial fibrillation, some tests may be necessary to check for potential contraindications and bad drug interactions to determine the best available option.
Patients with atrial fibrillation have an abnormal heart rate which can increase the risk of myocardial infarction and stroke. To address these concerns, a doctor may recommend anticoagulant therapy. This carries some risks, as patients may experience severe bleeding and hemorrhage, and anticoagulants can potentially increase the risk of stroke if not used carefully. In cases where such treatment is necessary to protect a patient, careful monitoring is necessary to check for signs of bad reactions.
One preferred therapy is warfarin, a highly effective anticoagulant. This medication can be risky and some patients do not tolerate it well, which makes alternatives necessary. Aspirin can offer some protection, but is not as effective and can also carry risks, particularly for patients with gastrointestinal problems. Clopidogrel for atrial fibrillation can be combined with aspirin to lower the risk of blood clot formation in a patient. For patients who need an alternative to warfarin, it can be very effective.
Clinical trials on clopidogrel for atrial fibrillation show that patients taking this medication in combination with aspirin have a lower risk of stroke and heart attack than those on placebo or aspirin alone. While it is not as efficacious as warfarin, in patients who cannot use the more powerful anticoagulant medication it can be highly suitable. One concern with clopidogrel for atrial fibrillation is the higher risk of uncontrolled bleeds, which makes it important to monitor the patient for signs of hemorrhage.
Therapies for atrial fibrillation and management of the associated risks periodically change as new medications are released and clinical trials provide more information. Patients considering clopidogrel for atrial fibrillation can talk to their doctors about all of the available options and may want to get information on the pros and cons of different available medications. It can also be possible to join a clinical trial to test out a new medication not yet available to the general public. If a patient is eligible for participation in a trial, a doctor can provide information and a referral.
